What Is Psilocybin Therapy?

Psilocybin therapy — formally psilocybin-assisted psychotherapy — is a structured clinical treatment that pairs a single (sometimes two) high-dose psilocybin session with structured preparation and integration psychotherapy around it. The dose used in published trials is typically 25 mg of synthetic pharmaceutical-grade psilocybin (the dose used in the Compass Pathways COMP360 Phase 2b TRD (treatment-resistant depression) trial, Goodwin 2022 NEJM). The dosing session itself runs 6 to 8 hours in a clinical setting, with two trained therapists present in most published protocols, eye shades, curated music, and continuous monitoring. The therapeutic mechanism — to the extent contemporary neuroscience can describe it — involves 5-HT2A serotonin receptor agonism, default mode network modulation, neuroplasticity, and the quality of the acute mystical-type experience as a meaningful mediator of long-term outcomes. This article walks through what psilocybin therapy actually is in 2026 clinical practice, why it differs from recreational mushroom use, what a session looks like, and where the honest limits of the evidence sit.

Key takeaways

• Psilocybin therapy uses synthetic pharmaceutical psilocybin (typically 25 mg in trials and Canadian SAP protocols) — NOT recreational mushrooms — administered in a supervised clinical setting.
• The standard model is three-phase: preparation (2–3 sessions), one or two dosing sessions (6–8 hours each), integration (2–4 sessions).
• Mechanism: 5-HT2A serotonin receptor agonism with downstream default mode network modulation, synaptic neuroplasticity, and mystical-type experience as mediator of long-term outcomes.
• Two therapists are typically present during dosing in published trial protocols; some clinical models use one. Eye shades and curated music are standard.
• Challenging experiences during dosing (anxiety, distress, fear, body horror, grief) are common and managed by the therapist team — they are not failures and are often integrated into therapeutic work.
• Psilocybin is Schedule III under the Canadian CDSA with no Health Canada approved indication; legal access is via the Special Access Program (SAP) only.

How psilocybin works in the brain

Psilocybin is rapidly converted in the body to psilocin, the active metabolite. Psilocin acts primarily as a partial agonist at 5-HT2A serotonin receptors in cortical pyramidal neurons. From this single receptor interaction, several downstream effects unfold.

Default mode network (DMN) modulation

The default mode network is a brain system implicated in self-referential thought, autobiographical memory, and rumination — and it is hyperactive in depression. Carhart-Harris et al. 2012, PNAS used fMRI to show that psilocybin decreases functional connectivity within the DMN during the acute experience. The magnitude of DMN deactivation correlated with the intensity of subjective effects in healthy volunteers, and subsequent work in TRD patients (Carhart-Harris et al. 2017) found that post-acute DMN connectivity changes correlated with antidepressant response.

The interpretive framework — sometimes called REBUS or "anarchic brain" (Carhart-Harris & Friston 2014) — is that psilocybin temporarily relaxes high-order cortical control, allowing flexible integration across networks that are normally segregated.

Neuroplasticity

Ly, Greb, Cameron et al. 2018, Cell Reports demonstrated that psychedelics including psilocybin promote rapid structural and functional neural plasticity — increased dendritic spine density, dendritic arbor complexity, and excitatory synapse formation in cortical neurons within hours of a single dose. The mechanism appears to involve TrkB / BDNF signalling and mTOR-pathway activation, similar to ketamine's effect through a different upstream receptor. This neuroplastic surge is hypothesized to create a "window of opportunity" during which integration psychotherapy and behavioural change consolidate the acute experience.

Mystical-type experience as mediator

A distinctive feature of psilocybin's therapeutic literature — different from ketamine's — is that the subjective quality of the acute experience correlates with long-term outcomes. Roseman, Nutt, Carhart-Harris 2018, Frontiers in Pharmacology demonstrated that the intensity of "oceanic boundlessness" (a measure of mystical-type experience) during dosing predicted antidepressant response in TRD; "dread of ego dissolution" predicted poorer response. The Mystical Experience Questionnaire (MEQ-30), validated by MacLean, Johnson, Griffiths 2011, J Psychopharmacol, is the standard instrument and assesses unity, transcendence of time/space, sacredness, noetic quality, and positive mood.

The honest framing: the mystical-experience-mediates-outcomes finding is robust across multiple psilocybin trials and is a meaningful difference from how ketamine appears to work. It does not mean every patient has a mystical experience or that those who don't won't benefit — but the quality of what happens during the dosing session matters.

Putting it together

The current best mechanistic story: 5-HT2A agonism produces an acute altered state characterized by DMN modulation and a phenomenology that often (not always) includes mystical-type elements; this acute state is paired with structured integration psychotherapy in a "window" of enhanced neuroplasticity to produce sustained psychological and behavioural change. Mechanism research is active and many specifics remain open questions.

The three-phase clinical model

Standard psilocybin-assisted therapy uses a three-phase structure across most published trial protocols (Carhart-Harris 2016, Davis 2021, Goodwin 2022, Bogenschutz 2022, Griffiths 2016, Ross 2016).

Phase 1: Preparation (2–3 sessions over 2–4 weeks)

Preparation sessions establish the therapeutic alliance, surface what the patient hopes to address, and prepare for the dosing experience. Standard elements:

• Rapport-building with the therapy team (typically two therapists in trial protocols; some clinical models use one)
• Informed consent including off-label/SAP regulatory framing, expected effects, and risks
• Personal history and intentions: trauma history, what's been tried, what the patient hopes for
• Set and setting orientation: how the dosing day will unfold; music preview; what to do if the experience becomes challenging
• Safety planning: emergency contacts, post-session support, behavioral commitments

Phase 2: Dosing session (one to two sessions, 6–8 hours each)

The dosing session is the longest and most intense phase. Most published trial protocols structure it as:

• Morning arrival: vitals; final medical screen; review of the day; settling into the dosing room
• Dose administration: 25 mg synthetic psilocybin orally (the dose used in Goodwin 2022 COMP001 / COMP360 TRD trial); slightly higher doses (e.g., 22 or 30 mg per 70 kg) in the Griffiths 2016 cancer trial; 0.3 mg/kg in the Ross 2016 NYU cancer trial
• Onset (20–50 minutes): mild perceptual changes; emotional opening; therapists primarily quiet and supportive
• Peak (1.5–3 hours after dose): maximum intensity; eye shades and music typically used; therapists offer non-directive grounding if needed; patient often goes inward
• Comedown (3–5 hours after dose): gradual return; brief discussion of emerging themes; therapists more conversational
• Discharge: ~6–8 hours total in clinic; designated driver required; no driving for the rest of the day

The dosing session is not a hallucinogen-aided talk-therapy session in the traditional sense. The therapists are predominantly quiet and present rather than active interpreters; the patient's internal experience is the work.

Phase 3: Integration (2–4 sessions over the weeks following)

Integration sessions are where insights from the dosing experience are translated into life change. Standard elements:

• Meaning-making of what arose during dosing (memories, emotions, insights, challenging content)
• Behavioural consolidation: what specific changes does the patient want to make?
• Relapse prevention and ongoing support planning
• Difficult-experience reframing: many patients have moments of intense fear, grief, or disorientation during dosing; integration is where these become productive rather than just distressing

The honest framing: integration is widely considered the phase that makes psilocybin-assisted therapy "therapy" rather than just a drug experience. The acute experience without integration may produce transient effects but is unlikely to produce sustained change.

Synthetic pharmaceutical psilocybin versus recreational mushrooms — the meaningful distinction

This distinction matters legally, pharmacologically, and clinically.

The clinical-recreational distinction matters. All published psilocybin therapeutic trials, all Health Canada SAP-approved psilocybin therapy, and all pharmaceutical pathways under regulatory consideration use synthetic pharmaceutical psilocybin. Recreational mushrooms are not clinical psilocybin therapy and are not legal to possess or use outside SAP authorization in Canada.

What psilocybin therapy is not

A few honest corrections to common misunderstandings:

• Psilocybin therapy is not a "trip with a guide." It is a structured clinical protocol with preparation, dosing, and integration, and it is currently legal in Canada only via the SAP pathway with prescriber authorization.
• Psilocybin therapy is not microdosing. Microdosing — sub-perceptual recurring doses — has popular interest but lacks published clinical evidence comparable to high-dose protocols. Microdosing is not the SAP-pathway clinical model.
• Psilocybin therapy is not a one-shot fix. The acute experience without integration psychotherapy is unlikely to produce sustained change. The 2-3 preparation sessions, the dosing session, and the 2-4 integration sessions are the model.
• Psilocybin therapy is not unique to psilocybin. Similar three-phase models with adapted parameters apply to MDMA-assisted therapy, ketamine-assisted therapy, and other psychedelic-assisted modalities. The core clinical infrastructure is shared.
• Psilocybin therapy is not replacement for antidepressants or other ongoing psychiatric care. Patients on SSRIs, SNRIs, lithium, atypical antipsychotics, and other ongoing care typically taper or hold specific medications around dosing under their prescriber's supervision; psilocybin therapy fits within an integrated psychiatric care model, not outside of it.

Challenging experiences — honest framing

A meaningful percentage of psilocybin dosing sessions include moments of intense fear, anxiety, body horror, grief, or disorientation. Clinical literature reframes these from "bad trips" to "challenging experiences" because they are often where therapeutic content emerges. Carbonaro et al. 2016, J Psychopharmacol surveyed psilocybin users about challenging experiences and found that most resolved without lasting harm; many participants reported positive long-term outcomes following challenging experiences when supported.

The therapist team's role during a challenging experience:

• Non-directive presence. Sit with the patient; do not actively redirect or psychoeducate during peak intensity.
• Grounding when needed: gentle physical reassurance, breathing cues, reorientation to the room.
• Safety: ensure the patient remains safe, hydrated, and oriented enough to communicate distress.

The honest framing: challenging experiences are common, are not failures, and are often integrated productively into the post-dosing therapeutic work. Pre-dosing preparation explicitly covers what to expect and how to navigate.

Eligibility — who is and is not a candidate

Most published psilocybin trials and Canadian SAP applications use these inclusion and exclusion criteria.

Generally eligible:

• Adults 18 or older
• Documented diagnosis of a SAP-eligible serious or life-threatening condition (cancer-related psychiatric distress, treatment-resistant depression, alcohol use disorder, demoralization, others case-by-case)
• Documented failure of conventional treatments at adequate dose and duration
• Medically stable; able to provide informed consent

Absolute contraindications:

• Personal history of psychotic disorder (schizophrenia, schizoaffective, bipolar I)
• First-degree family history of psychotic disorder (more conservative)
• Active mania or recent hypomania
• Uncontrolled cardiovascular disease, recent MI, severe structural heart disease
• Pregnancy
• Concurrent lithium (seizure case reports in published literature)
• Active substance use disorder requiring treatment

Relative contraindications and considerations:

• High-dose serotonergic antidepressants (theoretical serotonin syndrome risk; many trials taper SSRIs/SNRIs before dosing under prescriber supervision)
• Severe personality disorder with marked instability
• Complex trauma without adequate therapeutic alliance and prep capacity
• Significant cognitive impairment that interferes with informed consent

For the access deep dive, see How to Access Psilocybin Therapy in Canada.

Frequently asked questions

What is psilocybin therapy in plain language? Psilocybin therapy is a structured clinical model that pairs a single (sometimes two) high-dose psilocybin session — typically 25 mg of synthetic psilocybin — with preparation sessions before and integration sessions afterward, in a clinical setting with trained therapists.

What does the dosing session feel like? Onset is 20–50 minutes after taking the dose. Effects build to a peak at 1.5–3 hours that includes perceptual changes, emotional intensity, time distortion, and often what's called ego dissolution or mystical-type experience. The peak lasts 1–3 hours; total experience is 4–6 hours; you remain in clinic 6–8 hours total. Most patients lie down with eye shades, listen to curated music, and go inward.

Is the experience always positive? No. Challenging experiences — fear, grief, body horror, disorientation — are common and are part of the work, not a failure. Therapist team presence and integration sessions are how challenging content becomes productive.

How is this different from recreational mushrooms? Synthetic pharmaceutical psilocybin has known purity, exact dose, supervised setting, screened patients, and integration support. Recreational mushrooms have variable potency, no clinical screening, no integration, and are illegal to possess.

How is psilocybin therapy different from ketamine therapy? Different drug class (5-HT2A serotonin agonist vs NMDA antagonist), different session length (6–8 hours vs 90–120 minutes), different experience (classic psychedelic vs dissociative), different access (SAP-only vs off-label legal for ketamine; Spravato approved for TRD).

Will I be on a "trip"? "Trip" is recreational language. Clinical psilocybin therapy uses the clinical term "session" or "experience." The state is genuinely altered — perceptions change, emotions intensify, time distorts — but it is not a recreational pursuit. The therapeutic structure around it is what makes it therapy.

Can I do psilocybin therapy without medication tapering? Often yes for SSRIs/SNRIs, but specific medications (lithium absolutely; high-dose SSRIs sometimes) require tapering under prescriber supervision. The ATMA CENA intake call coordinates with your prescribing physician.

Will I remember everything? Most patients remember the dosing experience clearly, though the nature of the recall (linear vs symbolic) varies. Integration sessions help convert the experience into language and meaning.

How does ATMA CENA's preparation/integration model work? ATMA CENA's three-phase psychedelic-assisted therapy model — preparation, dosing support coordination, integration — adapts to psilocybin where SAP approval is in place. The medical SAP application is initiated by the patient's prescribing physician; ATMA CENA supports the psychotherapy wraparound. See Psilocybin Therapy in Canada for ATMA CENA's role.

Where can I get psilocybin therapy in Canada? Through SAP-authorized clinicians. TheraPsil maintains a directory of trained Canadian clinicians; Roots to Thrive in Nanaimo BC offers group programs; Quebec providers (Drs. Farzin and Stephan) have RAMQ public-funding precedent. ATMA CENA supports preparation and integration. See How to Access Psilocybin Therapy in Canada.

Sources

1. Carhart-Harris RL, et al. (2012). Neural correlates of the psychedelic state — DMN. PNAS. https://pubmed.ncbi.nlm.nih.gov/22308440/
2. Carhart-Harris RL, et al. (2017). Psilocybin for treatment-resistant depression — fMRI brain mechanisms. Sci Rep. https://pubmed.ncbi.nlm.nih.gov/29032520/
3. Ly C, Greb AC, Cameron LP, et al. (2018). Psychedelics promote structural and functional neural plasticity. Cell Reports. https://pubmed.ncbi.nlm.nih.gov/29898390/
4. Roseman L, Nutt DJ, Carhart-Harris RL (2018). Quality of acute psychedelic experience predicts therapeutic efficacy. Front Pharmacol. https://pubmed.ncbi.nlm.nih.gov/29387009/
5. MacLean KA, Johnson MW, Griffiths RR (2011). Mystical Experience Questionnaire validation. J Psychopharmacol. https://pubmed.ncbi.nlm.nih.gov/21674151/
6. Carbonaro TM, et al. (2016). Survey of challenging experiences with psilocybin. J Psychopharmacol. https://pubmed.ncbi.nlm.nih.gov/27578767/
7. Goodwin GM, et al. (2022). COMP360 psilocybin in TRD (Phase 2b RCT). NEJM. https://pubmed.ncbi.nlm.nih.gov/36322843/
8. Davis AK, et al. (2021). Psilocybin-assisted therapy for MDD. JAMA Psychiatry. https://pubmed.ncbi.nlm.nih.gov/33146667/
9. Griffiths RR, et al. (2016). Psilocybin in life-threatening cancer. J Psychopharmacol. https://pubmed.ncbi.nlm.nih.gov/27909164/
10. Ross S, et al. (2016). Psilocybin in cancer-related anxiety/depression. J Psychopharmacol. https://pubmed.ncbi.nlm.nih.gov/27909165/
11. Health Canada — SAP psychedelic-assisted psychotherapy: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html

Related articles in this cluster

• Psilocybin Therapy in Canada
• How to Access Psilocybin Therapy in Canada (SAP)
• Psilocybin-Assisted Therapy Cost in Canada
• Psilocybin Therapy for End-of-Life Distress
• Ketamine vs Psilocybin Therapy
• What Is Ketamine Therapy?

Last updated: 2026-05-06